Elicera Therapeutics AB (ELIC) AI Stock Analysis

Elicera Therapeutics AB

(Nasdaq OMX AB:ELIC)

Select Model

Rating:47Neutral

Price Target:SEK 3.00▲(12.99% Upside)

Action:reiterated

Date:09/06/26

The overall score is driven mainly by the weak financial profile of an early-stage, loss-making biotech with no current revenue and substantial ongoing cash burn, only partly mitigated by a solid, debt-free balance sheet and strengthened equity base. Secondary support comes from moderately positive short-term technical momentum and low volatility, while the lack of earnings-call insights, corporate events, dividends, and a meaningful P/E-based valuation keeps the stock’s attractiveness in the lower range of the scoring scale.

Positive Factors

Debt-free balance sheetA debt-free balance sheet reduces financial risk and avoids interest or refinancing burdens while the company advances its development programs. This gives management greater flexibility in allocating capital toward research, clinical work, and potential partnering activities over the next several quarters.

Negative Factors

No current TTM revenueRevenue has deteriorated sharply to zero on a trailing basis, indicating that the company currently lacks a commercial revenue stream to fund operations. Until partnering proceeds, product sales, or development milestones emerge, financial performance remains highly dependent on successful pipeline advancement.

Elicera Therapeutics AB (ELIC) vs. iShares MSCI Sweden ETF (EWD)

Market Cap: SEK 177.19M
Dividend Yield: ―
Average Volume (3M): 331.75K
Price to Earnings (P/E): -7.5
Beta (1Y): 0.25
Revenue Growth: ―
EPS Growth: 14.10%
Country: Sweden
Employees: 3
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

Elicera Therapeutics AB Business Overview & Revenue Model

Company Description

Elicera Therapeutics AB (publ), a Swedish immuno-oncology firm founded in Göteborg in 2014, is dedicated to the clinical development of cell and gene therapies that harness the immune system to combat cancer. Its promising pipeline features several d...

How the Company Makes Money

Elicera Therapeutics primarily aims to generate revenue through (1) out-licensing and partnering of its iTANK platform and/or specific therapeutic programs to other biotechnology or pharmaceutical companies, typically in exchange for upfront payments...

Elicera Therapeutics AB Financial Statement Overview

Summary

Financial performance is weak overall, with no current revenue, sizeable recurring operating and net losses, negative profit margins, and consistently negative returns, partially offset by a debt-free balance sheet and a strengthened equity and asset base that provide some cushion.

Income Statement

24Negative

Balance Sheet

68Positive

Cash Flow

30Negative

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	-147.66K	0	7.13M	11.23M	1.28M	587
Gross Profit	-147.66K	0	7.13M	11.22M	1.28M	-11.19K
EBITDA	-18.03M	-17.40M	-16.87M	-17.08M	-19.43M	-13.11M
Net Income	-17.98M	-17.41M	-16.11M	-16.40M	-19.52M	-13.12M
Balance Sheet
Total Assets	59.60M	27.42M	27.56M	30.18M	46.31M	54.74M
Cash, Cash Equivalents and Short-Term Investments	58.13M	24.85M	26.40M	29.38M	43.82M	52.39M
Total Debt	0	0	0	0	0	0
Total Liabilities	3.35M	4.06M	6.79M	13.78M	13.51M	2.50M
Stockholders Equity	56.25M	23.36M	20.77M	16.40M	32.80M	52.24M
Cash Flow
Free Cash Flow	-25.75M	-21.55M	-23.46M	-14.92M	-8.57M	-14.29M
Operating Cash Flow	-25.75M	-21.55M	-23.46M	-14.92M	-8.57M	-14.29M
Investing Cash Flow	0	1,000	0	483.17K	0	-1,000
Financing Cash Flow	44.21M	20.00M	20.48M	0	0	55.12M

Elicera Therapeutics AB Technical Analysis

Technical Analysis SentimentNegative

Last Price2.65

Price Trends

50DMA2.80Negative

100DMA2.72Negative

200DMA3.63Negative

Market Momentum

MACD-0.01Positive

RSI40.30Neutral

STOCH12.50Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:ELIC, the sentiment is Negative. The current price of 2.65 is below the 20-day moving average (MA) of 2.84, below the 50-day MA of 2.80, and below the 200-day MA of 3.63, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 40.30 is Neutral, neither overbought nor oversold. The STOCH value of 12.50 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:ELIC.

Elicera Therapeutics AB Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

SE:ELIC against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SE:CANTA	70Outperform	SEK 451.68M	2.35	63.09%	―	―	―
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SE:ELIC	47Neutral	SEK 177.19M	-7.51	-56.09%	―	―	14.10%
SE:ONCO	47Neutral	SEK 721.66M	-2.14	―	―	87.23%	35.27%
SE:BINV	43Neutral	SEK 357.32M	-0.73	-128.54%	―	-83.67%	-50.29%
SE:IMMU	43Neutral	SEK 348.89M	-3.07	-18.05%	―	―	15.97%
SE:ATORX	38Underperform	SEK 35.32M	-0.01	-439.98%	―	-99.33%	64.90%

* Healthcare Sector Average

Performance Comparison

SE:ELIC and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
SE:ELIC	Elicera Therapeutics AB	2.65	-3.44	-56.47%
SE:ATORX	Alligator Bioscience AB	0.01	-0.38	-97.42%
SE:BINV	BioInvent International AB	5.43	-28.47	-83.98%
SE:ONCO	Oncopeptides AB	1.67	-3.75	-69.16%
SE:IMMU	Immunicum AB	5.50	-1.89	-25.58%
SE:CANTA	Cantargia AB	1.60	-1.97	-55.13%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Sep 06, 2026

Elicera Therapeutics AB AI Stock Analysis